Interim total revenue was approx. 1,499,024 thousand yen, a 50.1% increase year-over-year. Operating income was 51 thousand yen, ordinary income was 7,357 thousand yen, and interim net income was 4,097 thousand yen. By segment, regenerative medicine products grew significantly, while contract regenerative medicine services declined. Lab site business was flat. The assumptions for next fiscal year\u2019s forecasts remain unchanged from those disclosed in May 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7774","jir_company_name":"Japan Tissue Engineering Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/7774-20261030-01.pdf","jir_short_summary":"Interim total revenue was approx. 1,499,024 thousand yen, a 50.1% increase year-over-year. Operating income was 51 thousand yen, ordinary income was 7,357 thousand yen, and interim net income was 4,097 thousand yen. By segment, regenerative medicine products grew significantly, while contract regenerative medicine services declined. Lab site business was flat. The assumptions for next fiscal year\u2019s forecasts remain unchanged from those disclosed in May 2026.","jir_summary":"### Overview of Performance\nSales during this interim period increased substantially year-over-year, with the regenerative medicine products business contributing particularly strongly. Total net sales were approximately 1,499 million yen, operating income returned to profitability, ordinary income was approximately 7.357 million yen, and interim net income was approximately 4.097 million yen. While sales of regenerative medicine products expanded significantly, contract regenerative medicine services declined and the lab site business showed a slight increase. Financial condition remains solid with total assets of 5,770 million yen and an equity ratio maintained at a high level of 88.3%. There are no changes to the assumptions underlying the earnings forecasts.\n\n### Segment Trends and Outlook\nThe regenerative medicine products business was driven by five core areas\u2014autologous cultured epidermis, cartilage, corneal epithelium, oral mucosal epithelium, and melanocyte-containing epidermis\u2014which boosted orders and sales. The contract regenerative medicine business experienced lower revenue as educational and know-how provision projects from the prior year tapered off, but demand for late-stage clinical trial support and regulatory affairs assistance is expected to expand. The lab site business is building a foundation for stable growth, including European expansion. Going forward, the company aims to grow sales through the dissemination of new pipeline products and partnership activities.","jir_financial_highlights":"Net Sales: 1,499,024 thousand yen (Year-over-Year +50.1%)\nOperating Income: 51 thousand yen (Year-over-Year -376,092 thousand yen)\nOrdinary Income: 7,357 thousand yen (Year-over-Year -369,121 thousand yen)\nInterim Net Income: 4,097 thousand yen (Year-over-Year -371,350 thousand yen)\nTotal Assets: 5,770,916 thousand yen (Compared with previous period +87,922 thousand yen)\nEquity Ratio: 88.3% (Compared with previous period -1.3 points)","jir_category":"","jir_hashtags":"#JapanTissueEngineering","jir_key_figures":"Net Sales: 1,499,024 thousand yen (Year-over-Year +50.1%)\nOperating Income: 51 thousand yen (Year-over-Year -376,092 thousand yen)\nInterim Net Income: 4,097 thousand yen (Year-over-Year -371,350 thousand yen)","jir_meta_title":"Japan Tissue Engineering Co., Ltd. Announces Interim Results | Regenerative Medicine Products Drive Revenue","jir_meta_description":"Analysis of Japan Tissue Engineering Co., Ltd.'s FY2027 second quarter interim financial summary. Net sales rose 50.1% year-over-year to approximately 149.9 hundred million yen, driven by growth in regenerative medicine products. Review of outlook and segment trends.","jir_og_title":"Analysis of Japan Tissue Engineering Co., Ltd.'s Interim Results","jir_og_description":"Regenerative medicine products are driving revenue and the company returned to operating profitability. Key points from the FY2027 second quarter interim financial summary explained clearly.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":57771,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-137058","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n